Semaglutide Protocol Guide: Physician-Supervised GLP-1 Therapy for Weight and Metabolic Optimization
Semaglutide is a long-acting GLP-1 receptor agonist that improves glycemic control, suppresses appetite, and produces clinically significant weight loss. Sold under the brand names Ozempic, Wegovy, and Rybelsus, Semaglutide is the most thoroughly studied GLP-1 in modern metabolic medicine.
Protocol Quick Reference
Who Is This Protocol For?
Semaglutide is suited for individuals seeking sustainable weight loss, improved glycemic control, or both. It is among the most evidence-backed metabolic peptides available and has been validated in large Phase 3 trials (STEP, SUSTAIN, PIONEER programs).
- Adults with elevated BMI seeking pharmacologic support for weight loss alongside lifestyle changes
- Those with insulin resistance or prediabetes wanting to improve glycemic control before progressing to diabetes
- Individuals with persistent appetite dysregulation — Semaglutide acts centrally to reduce food noise and cravings
- Patients with metabolic syndrome features including elevated triglycerides, low HDL, and central adiposity
- Anyone seeking the most-studied GLP-1 with the longest real-world track record
Semaglutide is not appropriate for individuals with personal or family history of medullary thyroid carcinoma or MEN-2, active pancreatitis, severe gastroparesis, pregnancy, or known hypersensitivity. A complete workup with your Hatter Labs physician precedes any prescription.
How Semaglutide Works: Mechanism of Action
Semaglutide selectively activates the glucagon-like peptide-1 (GLP-1) receptor, mimicking the endogenous incretin hormone produced in the gut after meals. Its modified amino acid sequence and fatty-acid side chain extend its half-life to roughly one week, enabling once-weekly dosing.
Primary Mechanisms
- Glucose-dependent insulin secretion: Enhances insulin release from pancreatic β-cells only when blood glucose is elevated, minimizing hypoglycemia risk in non-diabetics.
- Glucagon suppression: Reduces inappropriate glucagon release from α-cells, lowering hepatic glucose output.
- Delayed gastric emptying: Slows stomach emptying, prolonging satiety after meals and blunting postprandial glucose excursions.
- Central appetite regulation: Acts on hypothalamic GLP-1 receptors to reduce hunger signaling and food reward, lowering total caloric intake.
- Cardiometabolic improvements: Demonstrated reductions in MACE (major adverse cardiovascular events) in the SUSTAIN-6 and SELECT trials, alongside lipid and blood-pressure improvements.
Detailed Protocol
Semaglutide titration is gradual to minimize gastrointestinal side effects. Dose increases occur every four weeks based on tolerance and response.
| Phase | Weekly Dose | Duration |
|---|---|---|
| Starting | 0.25 mg subcutaneous | 4 weeks |
| Step Up | 0.5 mg subcutaneous | 4+ weeks |
| Therapeutic | 1.0 mg subcutaneous | 4+ weeks (if needed) |
| Maintenance | 1 – 2 mg subcutaneous | Ongoing |
| Maximum | 2 mg / week | Do not exceed |
Reconstitution Reference (BAC water)
| Vial | BAC Water | Dosage | Insulin Units | Total Doses |
|---|---|---|---|---|
| 5 mg | 2 mL | 0.25 mg | 10 | 20* |
| 5 mg | 2 mL | 0.5 mg | 20 | 10* |
| 5 mg | 2 mL | 1 mg | 40 | 5 |
| 10 mg | 2 mL | 0.5 mg | 10 | 20* |
| 10 mg | 2 mL | 1 mg | 20 | 10* |
| 10 mg | 2 mL | 2 mg | 40 | 5 |
*Concentrations yielding more than six doses per vial may compromise BAC water stability outside clinical settings. Slower titration is generally safer than rapid escalation.
Constipation Relief: Adding 200 mg magnesium glycinate at night is commonly recommended to mitigate constipation, a frequent GLP-1 side effect.
What to Expect: Results Timeline
Week 1-4: Acclimation Phase (0.25 mg)
- - Reduced hunger and meal size beginning within days
- - Mild nausea, fullness, or burping common; typically settles within 1-2 weeks
- - Initial weight loss of 1-3% body weight is common
- - "Food noise" significantly diminishes for most users
Week 5-16: Active Loss Phase (0.5 – 1 mg)
- - Steady weight loss of 1-2 lbs/week for most users
- - Improved fasting glucose and HbA1c
- - Lipid panel improvements becoming visible
- - Increased energy as metabolic flexibility improves
Month 4-12: Maintenance Phase (1 – 2 mg)
- - 10-15% total body weight loss is typical at therapeutic doses
- - Plateau is common around month 6-9; protocol reassessed
- - Long-term cardiometabolic improvements consolidated
- - Physician evaluates continuation, dose hold, or transition strategy
Potential Side Effects
Common (typically transient)
- Nausea, especially during titration
- Constipation or, less commonly, diarrhea
- Acid reflux or burping
- Reduced appetite (the desired effect, sometimes excessive)
- Fatigue during the first 1-2 weeks of each dose increase
Uncommon (report to your physician)
- Severe persistent vomiting or dehydration
- Signs of pancreatitis (severe upper abdominal pain radiating to back)
- Gallbladder symptoms (pain, jaundice)
- Hypoglycemia (more likely if combined with insulin or sulfonylureas)
- Significant muscle loss without resistance training and adequate protein
Safety Note: Maintain ≥1.6 g/kg body weight protein and resistance train 2-3x/week throughout the protocol to preserve lean mass. Aggressive caloric deficits without these inputs accelerate sarcopenia.
Stacking Options
Semaglutide + Cagrilintide
The dual amylin + GLP-1 stack mirrors Novo Nordisk's investigational CagriSema combination. Cagrilintide reactivates the satiety sensor and complements GLP-1 mechanism, and is particularly useful for breaking through plateaus.
Semaglutide + BPC-157
BPC-157 supports gastrointestinal lining health and may mitigate the GI side effects of GLP-1 therapy, particularly during titration.
Why Run Your Semaglutide Protocol with Hatter Labs
GLP-1 therapy is most effective when paired with metabolic labs, body composition tracking, and physician-led titration. Hatter Labs supports the entire protocol, from acclimation through maintenance.
Start Your Semaglutide ProtocolMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Semaglutide is a prescription medication. Individual results vary. Always consult a qualified healthcare provider before starting any peptide therapy. Hatter Labs protocols are supervised by licensed physicians who evaluate health history, contraindications, and treatment goals before prescribing.